---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009849"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:13:13.206747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients

## Summary
- Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.
- Study plans up to 30 participants; initial 1-year evaluation, possible extension to 3 years.
- First patient implants expected by July 2025; Principal Investigators Prof. David O'Neal and Assoc. Prof. Neale Cohen.
- CBGM is implantable, measures blood glucose directly (vs interstitial fluid), no wearable component.

## SEC filing metadata
- accession: 0001641172-25-009849
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000164117225009849/0001641172-25-009849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000164117225009849/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009849
- JSON: https://secwatch.observer/filing/0001641172-25-009849.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.